GO:2000426 negative regulation of apoptotic cell clearance: Efferocytosis Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000426 describes any process that stops, prevents or reduces the frequency, rate or extent of apoptotic cell clearance, also called efferocytosis.
• Negative regulation of efferocytosis is often mediated by macrophage-intrinsic checkpoints such as complement C3, Arid3a, Annexin A1 and TRIM28/miR133a/CD47 signaling.
• Tumor cells and dying cells can actively suppress clearance to evade immune surveillance and promote necrosis or chronic inflammation.
• Metabolic and epigenetic rewiring, including methionine use and DNMT3A activity, can modulate the resolution phase of efferocytosis.
• Loss of negative regulators such as SLC7A11 or Annexin A1 can improve efferocytosis and wound healing or remodel the immune microenvironment.
• CRISPR knockout, point mutation, knock-in and overexpression models are essential to dissect causal roles of these regulators in disease.
Description
Apoptotic cell clearance, or efferocytosis, is the process by which dying cells are recognized and removed by phagocytes such as macrophages and dendritic cells. This process is essential for tissue homeostasis, resolution of inflammation and prevention of autoimmunity. However, efferocytosis is not always beneficial in every context; it can be actively suppressed by negative regulators that limit the frequency or extent of clearance. GO:2000426, negative regulation of apoptotic cell clearance, captures this inhibitory layer of control. Understanding this term is critical because dysregulated suppression of efferocytosis contributes to atherosclerosis, cancer progression, cholestasis and impaired wound healing. Researchers studying this process need to identify the molecular brakes that prevent excessive or inappropriate clearance and to determine how these brakes can be therapeutically released.
negative regulation of apoptotic cell clearance At A Glance
| GO ID | GO:2000426 |
|---|---|
| GO term | negative regulation of apoptotic cell clearance |
| Ontology | biological_process |
| Synonym | negative regulation of efferocytosis; negative regulation of apoptotic cell removal; negative regulation of programmed cell clearance |
| Major function | Inhibits the recognition, engulfment or degradation of apoptotic cells by phagocytes |
| Representative regulators | Complement C3, factor H, Arid3a, Annexin A1, SLC7A11, TRIM28/miR133a/CD47, DNMT3A |
| Associated diseases | Atherosclerosis, pancreatic cancer, cholestasis, diabetes-impaired wound healing, pancreatic necrosis |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, flow cytometry, live imaging, RNA-seq, proteomics |
What Is GO:2000426?
GO:2000426 is a biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of apoptotic cell clearance. In other words, it encompasses all molecular events that inhibit the recognition, engulfment or degradation of apoptotic cells by phagocytes. This includes cell-autonomous mechanisms, such as complement factor H limiting C3 deposition on macrophages, and paracrine signals that impair Mertk-mediated efferocytosis. It also includes metabolic and epigenetic checkpoints that restrain the resolution phase of efferocytosis. The term is synonymous with negative regulation of apoptotic cell removal, negative regulation of efferocytosis and negative regulation of programmed cell clearance.
Why Is negative regulation of apoptotic cell clearance Important in Cell Biology?
Negative regulation of apoptotic cell clearance is important because it determines whether dying cells are efficiently removed or persist to drive inflammation, autoimmunity or tumor progression. In atherosclerosis, factor H-mediated limitation of macrophage efferocytosis exacerbates plaque formation. In pancreatic cancer, loss of Annexin A1 restrains efferocytosis and remodels the immune microenvironment through cGAS/STING activation. In cholestasis, Arid3a impairs Mertk-mediated efferocytosis, contributing to liver injury. In diabetes, targeting SLC7A11 improves efferocytosis by dendritic cells and accelerates wound healing. Thus, understanding this process offers therapeutic opportunities to modulate clearance in diverse diseases.
• Controls tissue homeostasis by preventing accumulation of apoptotic debris.
• Limits or exacerbates atherosclerosis through complement C3 and factor H.
• Modulates anti-tumor immunity in pancreatic cancer via Annexin A1 and cGAS/STING.
• Contributes to cholestatic liver injury through Arid3a-mediated Mertk suppression.
• Impairs wound healing in diabetes via SLC7A11-dependent mechanisms.
• Promotes pancreatic necrosis through TRIM28/miR133a/CD47 signaling.
• Involves epigenetic regulation by DNMT3A and methionine metabolism during resolution.
• Can trigger epithelial fate reprogramming during prostate regression.
• Represents a therapeutic target for inflammatory and metabolic diseases.
• Requires precise CRISPR models to distinguish causal regulators from bystanders.
What Happens During negative regulation of apoptotic cell clearance?
Recognition checkpoint: complement and opsonization
In simple terms: The body can put a 'do not eat' signal on dying cells or phagocytes to slow down clearance.
Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. Factor H acts as a negative regulator by preventing excessive C3 deposition on apoptotic cells or phagocytes, thereby reducing the rate of apoptotic cell clearance. This checkpoint is critical in atherosclerotic plaques, where impaired efferocytosis leads to necrotic core expansion.
Receptor-level inhibition: Mertk and Arid3a
In simple terms: Some proteins block the receptors that macrophages use to eat dying cells.
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis. Arid3a acts as a transcriptional or signaling brake that reduces Mertk-dependent recognition and engulfment of apoptotic cells, contributing to liver injury. This represents a direct negative regulation of the clearance machinery at the receptor level.
Metabolic and epigenetic brakes: methionine and DNMT3A
In simple terms: Macrophages use nutrients and DNA tags to decide whether to continue eating dying cells.
Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. This metabolic-epigenetic axis can also restrain excessive clearance, as DNMT3A-dependent methylation modulates the resolution phase. Negative regulation here ensures that efferocytosis is timely and not persistent, which is important for tissue repair.
Tumor and necrosis-associated suppression: Annexin A1, TRIM28/miR133a/CD47
In simple terms: Cancer cells and dying tissue can actively stop macrophages from clearing dead cells.
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels the immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. The TRIM28/miR133a/CD47 axis acts as a potential therapeutic target in pancreatic necrosis by impairing efferocytosis. These pathways represent pathological negative regulation that promotes tumor progression or necrosis.
Therapeutic reversal: SLC7A11 and wound healing
In simple terms: Blocking a negative regulator can restore the body's ability to clear dying cells and heal wounds.
Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. This demonstrates that negative regulation of apoptotic cell clearance is reversible and can be therapeutically exploited. Similarly, CNP ameliorates macrophage inflammatory response and atherosclerosis, indirectly affecting efferocytosis capacity.
Developmental and regression contexts: prostate regression
In simple terms: During tissue shrinkage, clearing dying cells can change what the remaining cells become.
Apoptotic cell clearance triggers epithelial fate reprogramming during prostate regression. Negative regulation of this clearance may therefore influence cell fate decisions and tissue remodeling. This highlights that the process is not only about debris removal but also about signaling outcomes.
Key Genes Involved in GO:2000426 negative regulation of apoptotic cell clearance
The following genes and proteins are experimentally validated regulators or effectors of negative regulation of apoptotic cell clearance (GO:2000426).
| Gene | Major Role | Research Relevance |
|---|---|---|
| C3 | Complement component; factor H limits its deposition to reduce efferocytosis | Atherosclerosis, macrophage efferocytosis |
| CFH | Factor H; cell-autonomous regulator of C3 that limits efferocytosis | Atherosclerosis, complement regulation |
| CNP | C-type natriuretic peptide; ameliorates macrophage inflammation and atherosclerosis | Atherosclerosis, macrophage biology |
| SLC7A11 | Cystine/glutamate antiporter; targeting improves efferocytosis in dendritic cells | Diabetes, wound healing |
| ANXA1 | Annexin A1; loss restrains efferocytosis and activates cGAS/STING | Pancreatic cancer, immune microenvironment |
| ARID3A | A+T rich interaction domain protein 3a; impairs Mertk-mediated efferocytosis | Cholestasis, liver injury |
| MERTK | Receptor tyrosine kinase; mediates apoptotic cell recognition and engulfment | Efferocytosis, cholestasis |
| DNMT3A | DNA methyltransferase; uses apoptotic cell-derived methionine during efferocytosis | Tissue resolution, epigenetics |
| TRIM28 | E3 ubiquitin ligase; part of TRIM28/miR133a/CD47 axis impairing efferocytosis | Pancreatic necrosis |
| MIR133A | MicroRNA; component of TRIM28/miR133a/CD47 axis | Pancreatic necrosis |
| CD47 | Don't-eat-me signal; impairs efferocytosis in pancreatic necrosis | Pancreatic necrosis, therapeutic target |
| GAS6 | Ligand for Mertk; involved in apoptotic cell recognition | Efferocytosis, cholestasis |
| PROS1 | Ligand for Mertk; involved in apoptotic cell recognition | Efferocytosis, cholestasis |
| STING1 | cGAS/STING pathway; activated upon Annexin A1 loss in macrophages | Pancreatic cancer, innate immunity |
| CGAS | DNA sensor; activated upon Annexin A1 loss in macrophages | Pancreatic cancer, innate immunity |
| IL10 | Anti-inflammatory cytokine; downstream of efferocytosis resolution | Tissue resolution |
| TGFB1 | Anti-inflammatory cytokine; downstream of efferocytosis resolution | Tissue resolution |
How Is negative regulation of apoptotic cell clearance Regulated?
Negative regulation of apoptotic cell clearance is controlled at multiple levels. Complement factor H limits C3 deposition on macrophages, acting as a cell-autonomous brake on efferocytosis. Arid3a impairs Mertk-mediated efferocytosis in cholestasis, likely through transcriptional or signaling interference. Metabolic inputs such as apoptotic cell-derived methionine and DNMT3A activity modulate the resolution phase, linking nutrient status to epigenetic control. In tumors, Annexin A1 loss restrains efferocytosis and activates cGAS/STING, while the TRIM28/miR133a/CD47 axis impairs clearance in pancreatic necrosis. These regulatory layers ensure that efferocytosis is context-dependent and can be therapeutically targeted.
negative regulation of apoptotic cell clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFH/C3 | Atherosclerosis | Macrophage-specific knockout or overexpression in Apoe-/- mice |
| ANXA1 | Pancreatic cancer | Macrophage-specific knockout in orthotopic pancreatic tumor models |
| ARID3A | Cholestasis | Liver-specific knockout or knock-in of Arid3a in bile duct ligation models |
| SLC7A11 | Diabetes-impaired wound healing | Dendritic cell-specific knockout or pharmacological inhibition in diabetic mice |
| TRIM28/CD47 | Pancreatic necrosis | Knockout or point mutation in pancreatic acinar cell models |
Atherosclerosis
Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. Impaired clearance of apoptotic cells in plaques leads to necrotic core formation and inflammation. CNP ameliorates macrophage inflammatory response and atherosclerosis, further linking efferocytosis regulation to plaque biology.
Pancreatic cancer and necrosis
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels the immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. The TRIM28/miR133a/CD47 axis acts as a potential therapeutic target in pancreatic necrosis by impairing efferocytosis. These findings highlight negative regulation of clearance as a driver of tumor progression and tissue necrosis.
Cholestasis and liver injury
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis. This negative regulation contributes to liver injury and impaired resolution. Targeting this axis may restore clearance and reduce cholestatic damage.
Diabetes and impaired wound healing
Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. This demonstrates that negative regulation of apoptotic cell clearance can be reversed to promote tissue repair. Metabolic control of efferocytosis is therefore a therapeutic opportunity in diabetic wounds.
From negative regulation of apoptotic cell clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of C3 regulation by factor H increase efferocytosis? | Macrophage-specific C3 or CFH knockout |
| Does Arid3a directly impair Mertk-mediated efferocytosis? | Arid3a knockout or point mutation in liver macrophages |
| Can SLC7A11 inhibition restore dendritic cell efferocytosis? | SLC7A11 knockout or overexpression in dendritic cells |
| Does Annexin A1 loss activate cGAS/STING in macrophages? | ANXA1 knockout in pancreatic tumor-associated macrophages |
| Does TRIM28/miR133a/CD47 axis impair efferocytosis? | TRIM28 knockout or miR133a knock-in in pancreatic necrosis models |
| Does DNMT3A mediate metabolic control of efferocytosis? | DNMT3A knockout or tagged knock-in in macrophages |
How to Study the negative regulation of apoptotic cell clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry with pHrodo | Internalization of apoptotic cells | Quantify efferocytosis in macrophages |
| Live-cell imaging | Real-time clearance rate and frequency | Study negative regulators that slow clearance |
| RNA-seq | Transcriptional changes during efferocytosis | Identify downstream pathways |
| ATAC-seq or methylation profiling | Epigenetic changes | Study DNMT3A and Arid3a mechanisms |
| Proteomics | Protein-level changes in phagocytes | Detect complement and Mertk signaling |
| Phosphoproteomics | Kinase signaling changes | Map receptor-level inhibition |
| CRISPR knockout screening | Causal genes for negative regulation | Identify novel brakes on efferocytosis |
| Overexpression models | Gain-of-function effects | Test if a gene is sufficient to inhibit clearance |
Flow cytometry-based efferocytosis assays
Flow cytometry using pHrodo-labeled apoptotic cells is a standard method to quantify efferocytosis rates in macrophages and dendritic cells. This method can distinguish surface-bound from internalized apoptotic cells and is compatible with CRISPR knockout or overexpression models.
Live-cell imaging and time-lapse microscopy
Live imaging of fluorescently labeled apoptotic cells and phagocytes allows real-time measurement of clearance frequency and rate. This is particularly useful for studying negative regulators that slow down but do not completely block efferocytosis.
Transcriptomics and epigenomics
RNA-seq and ATAC-seq or methylation profiling can reveal how negative regulators such as Arid3a or DNMT3A reprogram phagocytes during efferocytosis. These methods identify downstream pathways such as cGAS/STING or resolution cytokines.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can identify changes in Mertk signaling, complement deposition and metabolic enzymes during negative regulation of clearance. Phosphoproteomics is useful for detecting receptor-level inhibition.
How CRISPR Can Be Used to Study GO:2000426 negative regulation of apoptotic cell clearance
Knockout
CRISPR knockout of candidate negative regulators such as CFH, ARID3A, ANXA1 or SLC7A11 can test whether loss of function increases efferocytosis. Knockout models are essential to establish causality in diseases like atherosclerosis and cholestasis.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites in regulators like Mertk or Arid3a without deleting the entire protein. This is useful when complete knockout is lethal or confounded by developmental effects.
Knock-in
Knock-in of tagged versions of C3, DNMT3A or TRIM28 allows tracking of protein localization and interactions during negative regulation of efferocytosis. Knock-in of disease-associated variants can model human genetics.
Overexpression
Overexpression of negative regulators such as CD47 or factor H can test sufficiency to impair efferocytosis in vitro and in vivo. This approach is valuable for validating therapeutic targets.
How EDITGENE Supports negative regulation of apoptotic cell clearance Research
Researchers studying negative regulation of apoptotic cell clearance-related genes often need to determine whether a candidate gene is causally involved in suppressing efferocytosis or is merely a bystander. EDITGENE provides CRISPR-based cell models and screening services to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of apoptotic cell clearance research.
Frequently Asked Questions About negative regulation of apoptotic cell clearance
What is GO:2000426 negative regulation of apoptotic cell clearance?
GO:2000426 is a biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of apoptotic cell clearance, also called efferocytosis.
What genes are involved in negative regulation of apoptotic cell clearance?
Key genes include CFH, C3, ARID3A, MERTK, ANXA1, SLC7A11, TRIM28, MIR133A, CD47 and DNMT3A, as shown in recent studies.
How is negative regulation of efferocytosis studied?
Common methods include flow cytometry with pHrodo-labeled apoptotic cells, live-cell imaging, RNA-seq, proteomics and CRISPR knockout or overexpression models.
Why is negative regulation of apoptotic cell clearance important in atherosclerosis?
Factor H limits macrophage efferocytosis by regulating complement C3, which exacerbates atherosclerosis. CNP also ameliorates macrophage inflammation and atherosclerosis.
What is the role of Annexin A1 in efferocytosis?
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels the immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway.
How does Arid3a affect efferocytosis?
Arid3a impairs Mertk-mediated efferocytosis in cholestasis, contributing to liver injury.
Can targeting SLC7A11 improve wound healing?
Yes, targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes.
What is the TRIM28/miR133a/CD47 axis?
It is a pathway that impairs efferocytosis and acts as a potential therapeutic target in pancreatic necrosis.
How does DNMT3A regulate efferocytosis?
Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution.
What CRISPR models are used to study negative regulation of apoptotic cell clearance?
Knockout, point mutation, knock-in and overexpression models are used to test causal roles of genes like CFH, ARID3A, ANXA1 and CD47.
Conclusion
GO:2000426 negative regulation of apoptotic cell clearance is a critical biological process that controls the extent and timing of efferocytosis. Its dysregulation contributes to atherosclerosis, cancer, cholestasis, diabetes-impaired wound healing and pancreatic necrosis. Understanding the molecular brakes such as factor H, Arid3a, Annexin A1, SLC7A11 and TRIM28/miR133a/CD47 offers therapeutic opportunities to restore or inhibit clearance in a context-dependent manner. CRISPR-based models and multi-omics methods are essential to dissect these mechanisms and translate them into clinical applications.
References
- 1. Kiss MG et al.. 2023. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis.. Immunity 56(8):1809-1824.e10 PMID: 37499656
- 2. Bao Q et al.. 2024. CNP Ameliorates Macrophage Inflammatory Response and Atherosclerosis.. Circ Res 134(8):e72-e91 PMID: 38456298
- 3. Maschalidi S et al.. 2022. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes.. Nature 606(7915):776-784 PMID: 35614212
- 4. Hou Z et al.. 2024. Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway.. J Immunother Cancer 12(9) PMID: 39237260
- 5. Chen R et al.. 2023. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.. J Hepatol 79(6):1478-1490 PMID: 37659731
- 6. Ampomah PB et al.. 2022. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution.. Nat Metab 4(4):444-457 PMID: 35361955
- 7. Zhu Q et al.. 2024. The TRIM28/miR133a/CD47 axis acts as a potential therapeutic target in pancreatic necrosis by impairing efferocytosis.. Mol Ther 32(9):3025-3041 PMID: 38872307
- 8. Graham-Paquin AL et al.. 2026. Apoptotic cell clearance triggers epithelial fate reprogramming during prostate regression.. Cell Death Dis 17(1) PMID: 41963285
